Your session is about to expire
What is Ibrutinib
IbrutinibThe Generic name of this drug
Treatment SummaryIbrutinib is a medication that works by blocking the Burton's tyrosine kinase. It was approved by the FDA in 2013 for the treatment of mantle cell lymphoma and in 2014 for the treatment of chronic lymphocytic leukemia and Waldenström's Macroglobulinemia. In 2017, it was approved to treat chronic graft-versus-host-disease. Ibrutinib is also approved in Europe for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
Imbruvicais the brand name
Ibrutinib Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Imbruvica
Ibrutinib
2013
7
Effectiveness
How Ibrutinib Affects PatientsIn laboratory tests, this drug has been shown to cause CLL cells to die and to reduce the survival, growth, and movement of CLL cells. It also reduces the amount of certain proteins that help CLL cells survive. In clinical trials with people, this drug was found to help 71% of people with relapsed/refractory CLL, 70% of people with relapsed/refractory mantle cell lymphoma, 15-20% of people with relapsed/refractory diffuse large B-cell lymphoma, 75% of people with relapsed/refractory Waldenstrom's macroglob
How Ibrutinib works in the bodyIbrutinib works by forming a strong bond with a specific protein in the body called Bruton's Tyrosine Kinase (BTK). This bond prevents BTK from working properly, which in turn stops phosphorylation from happening in cells. As a result, ibrutinib helps to reduce inflammation and other symptoms associated with B-cell receptor signaling.
When to interrupt dosage
The endorsed dosage of Ibrutinib is contingent upon the identified condition, including Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. The quantity of dosage is subject to the technique of administration specified in the table below.Condition
Dosage
Administration
rituximab
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Chronic Lymphocytic Leukemia
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Mantle Cell Lymphoma
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Lymphoma
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
previously treated
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Waldenstrom Macroglobulinemia
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
failure of at least one prior systemic therapy
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Disease
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Warnings
There are 20 known major drug interactions with Ibrutinib.Common Ibrutinib Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Acteoside.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Ibrutinib.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Ibrutinib.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Antilymphocyte immunoglobulin (horse).
Ibrutinib Toxicity & Overdose RiskTests have not shown that ibrutinib causes changes to bacteria or chromosomes, or affects fertility. It is unknown whether ibrutinib causes cancer or affects fertility.
Ibrutinib Novel Uses: Which Conditions Have a Clinical Trial Featuring Ibrutinib?
Currently, 267 active trials are assessing the efficacy of Ibrutinib in providing relief for Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.Condition
Clinical Trials
Trial Phases
Disease
19 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable
Mantle Cell Lymphoma
97 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Lymphoma
51 Actively Recruiting
Phase 2, Phase 1, Phase 3
Chronic Lymphocytic Leukemia
4 Actively Recruiting
Phase 1
rituximab
0 Actively Recruiting
previously treated
0 Actively Recruiting
failure of at least one prior systemic therapy
0 Actively Recruiting
Waldenstrom Macroglobulinemia
8 Actively Recruiting
Phase 2, Phase 1
Ibrutinib Reviews: What are patients saying about Ibrutinib?
5Patient Review
10/19/2017 The drug is very good, but it comes with some side effects. The biggest problem, by far, is the cost. I also get gout periodically, and that can be quite painful. This has been the best treatment for me so far, but the cost may be preventing other people from getting access to it.
5Patient Review
3/4/2017 Ibrutinib has been a godsend. I was diagnosed with mantle cell lymphoma 12 years ago and have since undergone three rounds of chemotherapy. This is my last chance, and so far it's working wonders. I'm 78 years old and still very active.
5Patient Review
8/7/20144.7Patient Review
7/8/2015 I have cll for 10 years. This treatment has led to a reduction in lymph node and spleen size, as well as decreased lymphocytes (although they initially increased). Platelets are a little low and mild-moderate diarrhoea is present. Otherwise, I'm doing well after 4 months of treatment.
4.7Patient Review
8/7/2018 I've had some tolerable side effects. I'm on my first year of Imbruvica (after 12 years and 4 different chemos), and so far it's working great. No new nodes have popped up anywhere, just some minor pains in my joints (gout). Thanks, Imbruvica!
4.3Patient Review
7/25/2021 I've only been on this medication for three weeks, but I have definitely noticed an improvement in my energy levels. The main side effects I've experienced are pain in my bones, muscles, and joints.
4Patient Review
8/1/2019 My anemia has improved a lot, but I still get short of breath sometimes. I walk every day, but I'm not as fast as I used to be. A year ago, I needed a wheelchair often, so this progress is great!
4Patient Review
4/15/2018 I found this treatment to be effective, but I was surprised at how much it cost in the United States compared to India.
1.7Patient Review
10/5/2017 The monthly co-pay is absolutely outrageous, especially for those of us on Medicare Part D. I can't imagine having to stay on this medication for the rest of my life without any help.
Patient Q&A Section about ibrutinib
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is ibrutinib used for?
"IMBRUVICA is a prescription medicine used to treat mantle cell lymphoma and chronic lymphocytic leukemia in adults who have received at least one prior treatment."
Answered by AI
How long can you survive ibrutinib?
"Imbruvica therapy has an average duration of 41 months, with a range of 2 to 51 months in clinical trials. For people who have stopped Imbruvica, the average survival after treatment discontinuation was 8 months."
Answered by AI
What is the drug ibrutinib used for?
"This medication is used to treat certain cancers, such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia. Ibrutinib belongs to a class of drugs known as kinase inhibitors, which work by slowing or stopping the growth of cancer cells."
Answered by AI
Is ibrutinib a chemo?
"This knowledge has led to the development of new drugs that can target cancer cell's specific vulnerabilities.
Targeted therapies, like ibrutinib, are not chemotherapy drugs. They are the result of years of research dedicated to understanding the differences between cancer cells and normal cells. This knowledge has led to the development of new drugs that can target cancer cell's specific vulnerabilities."
Answered by AI
How long do you take ibrutinib for CLL?
"If you experience disease progression or unacceptable toxicity while taking Imbruvica, your doctor may decide to discontinue your treatment. The average duration of Imbruvica therapy in clinical trials for CLL has been 41 months (with a range of 2-51 months)."
Answered by AI
What type of drug is ibrutinib?
"Ibrutinib is a growth blocker that inhibits tyrosine kinases. Tyrosine kinases are enzymes that send growth signals to cells. Ibrutinib stops the cell from growing and dividing by blocking the tyrosine kinases."
Answered by AI